title: Impact of fixed-dose combination drugs on adherence to prescription medications.
abstract: BACKGROUND
  The inverse correlation between the complexity of a drug regimen and medication adherence is well established. Fixed-dose combination (FDC) therapies are hypothesized to enhance compliance by decreasing the number of required pills.
  
  
  OBJECTIVE
  The objective of the study is to compare adherence of a FDC [Glucovance, a FDC of metformin and glyburide] to a 2-pill regimen.
  
  
  METHODS
  Longitudinal data from a large claims database were used to assess adherence from January 1, 2000, to December 31, 2001. Propensity scoring methods were used to mitigate concerns related to non-random assignment of patients to treatments.
  
  
  METHODS
  The subjects of the study were individuals prescribed metformin or sulfonylurea or both before July 2000, who were prescribed both metformin and sulfonylurea concurrently (either separately or FDC) after August 2000.
  
  
  METHODS
  Adherence was measured by medication possession ratio; the proportion of days on which a patient had medication available.
  
  
  RESULTS
  The FDC enhanced adherence rates by approximately 13% when compared to a 2-pill regimen.
  
  
  CONCLUSIONS
  Compared to 2-pill therapy, a FDC resulted in important increases in patient adherence. Economic analyses are warranted to determine whether the clinical benefits attributable to the adherence gains are worth the incremental cost of a FDC.
authors.affiliation: Department of Health Management and Policy, University of Michigan, Ann Arbor, MI, USA.
authors.forename: Feng
authors.initials: F
authors.lastname: Pan
authors.forename: Michael E
authors.initials: ME
authors.lastname: Chernew
authors.forename: A Mark
authors.initials: AM
authors.lastname: Fendrick
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D003920:Diabetes Mellitus / Q000188:drug therapy*; D004334:Drug Administration Schedule; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D005905:Glyburide / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D008297:Male; D008687:Metformin / Q000008:administration & dosage / Q000627:therapeutic use; D008875:Middle Aged; D010349:Patient Compliance
chemical_list: D004338:Drug Combinations; C417231:Glucovance; D007004:Hypoglycemic Agents; D008687:Metformin; D005905:Glyburide